These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1316 related items for PubMed ID: 23527621

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Biosimilar safety considerations in clinical practice.
    Choy E, Jacobs IA.
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Epoetin biosimilars in Europe: five years on.
    Mikhail A, Farouk M.
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T, Jordan JB, Akers C, Patel B, Drago D.
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biosimilars and the European experience: implications for the United States.
    Megerlin F, Lopert R, Taymor K, Trouvin JH.
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [Abstract] [Full Text] [Related]

  • 16. Similar names for similar biologics.
    Casadevall N, Felix T, Strober BE, Warnock DG.
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [Abstract] [Full Text] [Related]

  • 17. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC, Sinogas C, Albuquerque de Almeida F, Baptista-Leite R, Castro-Caldas A.
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [Abstract] [Full Text] [Related]

  • 18. Biosimilar safety factors in clinical practice.
    Reinisch W, Smolen J.
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [Abstract] [Full Text] [Related]

  • 19. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M, Stead D, Lukas M, Scotte F, Schmid H.
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [Abstract] [Full Text] [Related]

  • 20. [Biosimilars].
    Krämer I.
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.